Ocular adverse events due to PD-1 and PD-L1 checkpoint inhibitors: A retrospective review of FDA adverse events reporting system (FAERS)

被引：0

作者：

Sahu, Y. ^{[1
]}

Ensor, J. ^{[2
]}

Burns, E. ^{[3
]}

Sahu, G. ^{[4
]}

Iyer, S. P. ^{[5
]}

Anand, K. ^{[6
]}

机构：

[1] Safdarjang Hosp, Opthalmol, New Delhi, India

[2] Houston Methodist Res Inst, Oncol, Houston, TX USA

[3] Houston Methodist Hosp, Canc Ctr, Houston, TX 77030 USA

[4] Creighton Univ, Sch Med, Psychiat, North Platte, NE USA

[5] Univ Texas MD Anderson Canc Ctr, Lymphoma Myeloma, Houston, TX 77030 USA

[6] Great Plains Hlth, Canc Ctr, North Platte, NE USA

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.10.530

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

43P

引用

页码：S1433 / S1433

页数：1

共 50 条

[1] Ocular adverse events in PD-1 and PD-L1 inhibitors
Young, LeAnne
Finnigan, Shanda
Streicher, Howard
Chen, Helen X.
Murray, James
Sen, H. Nida
Sharon, Elad
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (07)
[2] PD-1/PD-L1 inhibitors-associated cardiac adverse events: a retrospective and real-world study based on the FDA Adverse Event Reporting System (FAERS)
Wang, Qiaoyun
Xiao, Fengjiao
Zeng, Yanbin
Zhu, Qiaoling
Zhang, Haixia
EXPERT OPINION ON DRUG SAFETY, 2024, 23 (02) : 257 - 267
[3] Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
Zhou, Yanting
Li, Hongyan
FRONTIERS IN NEUROSCIENCE, 2023, 17
[4] Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database
Frey, Connor
Etminan, Mahyar
ANTIBODIES, 2024, 13 (03)
[5] Endocrine system-related adverse events associated with PD-1/PD-L1 inhibitors: data mining from the FDA adverse event reporting system
Shi, Hongxia
He, Yunhua
Dan, Siyuan
Yang, Lin
Wang, Jing
Chen, Li
Chen, Zelian
FRONTIERS IN MEDICINE, 2024, 11
[6] Disproportionality analysis of bullous pemphigoid adverse events with PD-1 inhibitors in the FDA adverse event reporting system
Aggarwal, Pushkar
EXPERT OPINION ON DRUG SAFETY, 2019, 18 (07) : 623 - 633
[7] Adverse reactions associated with SSRIs and PD-1/PD-L1 inhibitors: a disproportionality analysis of the FDA Adverse Event Reporting System
Dong, Jiaqi
Liu, Mingyue
Li, Suning
Zhang, Siqi
Fu, Pengbin
Liu, Mengya
Jin, Shasha
Fan, Chunliang
Fang, Mingzhu
Wu, Liang
Li, Zhe
EXPERT OPINION ON DRUG SAFETY, 2025,
[8] Therapy monitoring and management of adverse events in PD-1/PD-L1 immune checkpoint inhibition
Oppel-Heuchel, H.
Grimm, M. -O.
UROLOGE, 2016, 55 (05): : 677 - 688
[9] Retrospective analysis of immune-related adverse events of the immune checkpoint inhibitors of PD-1/PD-l1 in the Fujian provincial hospital
Zheng, Jianping
Cui, Tongjian
Gao, Yu
Li, Ting
EUROPEAN JOURNAL OF INFLAMMATION, 2022, 20
[10] Autoimmune cutaneous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the FDA Adverse Event Reporting System from the Research on Adverse Drug Events and Reports program
Memon, Rohail
Kelm, Ryan C.
Erickson, Maia K.
Choi, Jennifer N.
Laumann, Anne E.
West, Dennis P.
Nardone, Beatrice
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB142 - AB142

← 1 2 3 4 5 →